今日热点！星光熠熠！恰尔汗奥卢、居莱尔领衔土耳其队征战欧洲杯

星光熠熠！恰尔汗奥卢、居莱尔领衔土耳其队征战欧洲杯

北京时间2024年6月16日讯，土耳其国家队公布了参加2024年欧洲杯的26人大名单，效力于国际米兰的哈坎·恰尔汗奥卢和效力于皇家马德里的卡里姆·居莱尔两大巨星领衔出战。

恰尔汗奥卢和居莱尔都是土耳其队当之无愧的核心球员，两人在各自俱乐部都展现出了出色的状态。恰尔汗奥卢在意甲联赛中贡献了10个进球和15次助攻，是国际米兰夺冠的重要功臣之一。居莱尔则在西甲联赛中打进了23个进球，荣膺西甲金靴，帮助皇马夺得联赛冠军。

除了这两位巨星之外，土耳其队还征召了效力于罗马的泽基·切利克、效力于本菲卡的奥古赞·柯克曲、效力于多特蒙德的埃姆雷·坎等实力强劲的球员。整体而言，土耳其队阵容完整，攻守兼备，是本届欧洲杯的一支不可忽视的力量。

土耳其队曾在2008年欧洲杯上获得第三名，创造了队史最佳战绩。此次征战欧洲杯，土耳其队期待能够再次创造佳绩。

以下是土耳其队欧洲杯26人大名单：

**门将：**乌古尔·恰克尔（特拉布宗体育）、梅尔特·居诺克（贝西克塔什）、阿尔泰·巴因德尔（曼联）

**后卫：**泽基·切利克（罗马）、梅尔特·穆尔德尔（费内巴切）、恰格拉尔·索伊萨尔（莱斯特城）、德米尔·德米拉尔（吉达国民）、卡纳伊·阿卡伊登（帕纳辛奈科斯）、乌fuk Bekir Özkara (瓦伦西亚)、马兹·卡迪奥卢（费内巴切）

**中场：**哈坎·恰尔汗奥卢（国际米兰）、伊尔汉·帕夫拉奇（莱斯特城）、奥古赞·柯克曲（本菲卡）、多纳塔斯·于克塞克（费内巴切）、伊克艾尔姆·艾汉（加拉塔萨雷）、埃姆雷·坎（多特蒙德）、哈维尔·奥尔塔（利兹联）

**前锋：**卡里姆·居莱尔（皇家马德里）、布拉希姆·达里（莱斯特城）、恩尼斯·乌纳尔（伯恩茅斯）、尤苏夫·亚兹哲（里尔）、哈坎·卡赫韦奇（费内巴切）、阿尔达·图尔古特（马赛）

**主教练：**斯特凡诺·皮奥利（意大利）

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.